

CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

Email ID: complianceofficer@concordbiotech.com

July 22, 2025

To The Manager, Listing Department National Stock Exchange of India Ltd. Plot No. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai -400 051 Symbol: CONCORDBIO	To General Manager, Listing Department BSE Limited Phiroze Jeejabhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 543960
---	---

Dear Sir/Ma'am,

Sub.: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Incorporation of a Wholly Owned Subsidiary Company (WOS).

We are pleased to announce incorporation of Concord's Wholly Owned Subsidiary Company, namely, "Concord Lifegen Limited" with objective to carry out marketing, sales, and distribution of pharmaceutical products.

Disclosure is given in terms of the above referred provisions of SEBI Regulations, read with circular dated November 11, 2024 issued by the Securities and Exchange Board of India, bearing ref. no. SEBI/HO/CFD/PoD2/CIR/P/0155 ("said SEBI Circular").

The requisite details of terms of the provisions of Regulation 30 read with Schedule III of the SEBI Regulations and the said SEBI circular, are included in Annexure A, as enclosed herewith.

This is for your information and records.

For Concord Biotech Limited

Hina Patel
Company Secretary and Compliance Officer
(ACS:56541)

Encl : As above

CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

Email ID: complianceofficer@concordbiotech.com

Annexure-A

Sr. No.	Particulars	Details
a)	Name of the target entity, details in brief such as size, turnover etc.	CONCORD LIFEGEN LIMITED , Incorporated under Companies Act, 2013. Authorised Share Capital (as on July 22,2025): Rs. 1,00,000 divided into 10,000 equity shares of Rs. 10 Each Issued share capital (as on July 22, 2025): Rs. 1,00,000 divided into 10,000 equity shares of Rs. 10 Each Turnover:- Concord Lifegen Limited is yet to commence business
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at arm's length	Concord Lifegen Limited is wholly owned subsidiary of Concord Biotech Limited. Therefore, the said investment would fall under the purview of Related Party Transaction. This investment and subscription of shares will be at arm's length basis. Yes, the promoter/ promoter group/ group companies have interest.
c)	Industry to which the entity being acquired belongs	Biopharmaceutical Industry
d)	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The Wholly Owned Subsidiary Company is Incorporated to manage the marketing, sales, and distribution of pharmaceutical products. Its primary objectives include executing targeted sales strategies, ensuring regulatory compliance across domestic and international markets, handling logistics and customer support, and maintaining transparent reporting to the holding company.
e)	brief details of any governmental or regulatory approvals required for the acquisition;	Not Applicable

CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeval Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

Email ID: complianceofficer@concordbiotech.com

f)	indicative time period for completion of the acquisition	The equity shares against the current investment will be allotted within 90 days from the Investment.											
g)	consideration – whether cash consideration or share swap or any other form and details of the same;	Cash Consideration											
h)	cost of acquisition and/or the price at which the shares are acquired;	Rs. 1,00,000/-											
i)	percentage of shareholding / control acquired and / or number of shares acquired;	100% in the equity of Concord Lifegen Limited.											
j)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	The WOS Company is dedicated to the marketing, sales, and distribution of pharmaceutical products with the aim of enhancing commercial efficiency, ensuring regulatory compliance across domestic and international markets, and strengthening customer engagement. Brief Details of LifeGen are as under: <table><tr><th>Particulars</th><th>Details</th></tr><tr><td>Registration Number</td><td>U21002GJ2025PLC165303</td></tr><tr><td>Date of Incorporation</td><td>July 21 ,2025</td></tr><tr><td>History of last 3 years' Turnover</td><td>NIL</td></tr><tr><td>Country of Presence</td><td>India</td></tr></table>		Particulars	Details	Registration Number	U21002GJ2025PLC165303	Date of Incorporation	July 21 ,2025	History of last 3 years' Turnover	NIL	Country of Presence	India
Particulars	Details												
Registration Number	U21002GJ2025PLC165303												
Date of Incorporation	July 21 ,2025												
History of last 3 years' Turnover	NIL												
Country of Presence	India												